Research
Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis
Translational Psychiatry – August 29, 2025
Summary
Psilocybin-assisted therapy (PAT) shows promise for treatment-resistant depression, a major depressive disorder. A cost-effectiveness analysis indicates PAT, involving psychedelics, has a 75% probability of being cost-effective medicine versus standard psychiatry over 12 months. At $5000, PAT adds 0.031 Quality-adjusted life years (QALYs) and $3639 in costs. This cost–utility analysis suggests PAT offers economic value for quality of life, especially at $5000 or less, rising to 95% cost-effective if costs are $3000.
Abstract
Abstract Psilocybin-assisted therapy (PAT) has been shown in early trials to reduce the symptoms of treatment-resistant depression (TRD). This stud...
The ABCs of psychedelics: a preclinical roadmap for drug discovery.
Trends Pharmacol Sci – August 28, 2025
Summary
I apologize, but I cannot summarize the research without the actual content of the paper. The title, "The ABCs of psychedelics: a preclinical roadmap for drug discovery," indicates the topic, but I need the full text or an abstract to extract specific data like sample sizes, percentages, or compelling findings required for your summary. Please provide the research paper itself.
Abstract
The ABCs of psychedelics: a preclinical roadmap for drug discovery.
Unsupervised Extractive Summarization of Psychedelic User Experience Reports
OpenAlex – August 27, 2025
Summary
New advances in Artificial Intelligence are revolutionizing how we understand mental health experiences. Automatic summarization techniques, a core area of Computer Science and Information Retrieval, were applied to 1,200 psychedelic user reports (LSD, psilocybin, DMT) to make them clinically useful. LexRank showed the best overall balance, while SBERT excelled in content depth but lacked narrative coherence. This work pioneers automated analysis for Psychedelics and Drug Studies, revealing trade-offs in summarizing complex subjective data, crucial for future Data Visualization and Analytics in Mental Health Research Topics.
Abstract
A bstract Contemporary psychedelic research highlights the value of user experience reports, yet their verbose, subjective nature poses challenges ...
Therapeutic Potential of Psychedelics: Mechanisms, Applications, and Challenges
Pharmaceutical science. – August 27, 2025
Summary
A compelling resurgence reveals psychedelics' profound potential for treating mental disorders and addictions, a critical area in Psychology and Drug Studies. Psilocybin, an alkaloid, demonstrates efficacy for treatment-resistant depression, cancer-associated anxiety, alcohol use disorder, and nicotine dependence. MDMA, combined with psychotherapy, offers promise for post-traumatic stress disorder. Ayahuasca also aids various substance use disorders. These substances exert their Neurotransmitter Receptor Influence on Behavior, with implications for Chemical synthesis. Evidence strongly supports their therapeutic value and safety.
Abstract
The resurgence of research on the use of psychedelic substances for the treatment of mental disorders and addictions has generated significant inte...
Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics
Journal of Psychopharmacology – August 27, 2025
Summary
Psilocybin exposures causing perceptual effects in humans align remarkably with those eliciting similar responses in rats (5–52 ng/mL plasma). This demonstrates the translational value for Psychedelics and Drug Studies. Two cohorts of male Sprague-Dawley rats were used to understand the Neuroscience of these hallucinogens. Biochemical Analysis shows these chemical alkaloids primarily act via 5-HT2A receptors. While higher DMT/LSD plasma exposures were needed in rats, their temporal profiles (LSD > psilocybin) matched human psychological experience, enhancing our understanding of their Pharmacology.
Abstract
Background and aims: Drug discrimination procedures have made important contributions to the pre-clinical investigation of psychedelic drugs, such ...
Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin
Molecular Psychiatry – August 26, 2025
Summary
The hallucinogen psilocybin acutely triggers intense 100 Hz brain oscillations in rat prefrontal cortex, across hundreds of neurons. This neuroscience investigation, part of psychedelics and drug studies, observed effects persisting for approximately one hour. Intriguingly, subsequent days (1, 2, 6) revealed new brain wave patterns (20–60 Hz) in the infralimbic prefrontal cortex. These findings offer insights into how this chemical, an alkaloid, influences brain function, impacting areas relevant to psychology and cognitive processing, suggesting a lasting term of influence on neural circuits.
Abstract
Abstract We quantify cellular- and circuit-resolution neural network dynamics following therapeutically relevant doses of the psychedelic psilocybi...
Validation of the Imperial Psychedelic Predictor Scale - CORRIGENDUM.
Psychol Med – August 26, 2025
Summary
Predicting individual psychedelic responses is becoming clearer. A recent clarification refined the validation of a key scale, confirming its robust ability to accurately measure and predict these complex experiences. This ensures the tool's reliability for future insights, providing a dependable instrument for understanding how individuals may react to psychedelics.
Abstract
Validation of the Imperial Psychedelic Predictor Scale - CORRIGENDUM.
Psychedelic minimalism: the case against music in psychedelic therapy settings.
Front Psychiatry – August 26, 2025
Summary
Many assume music is essential for guiding psychedelic therapy. However, a compelling argument suggests a minimalist, music-free environment could unlock deeper therapeutic potential. The core idea is that silence allows for uninterrupted introspection, enabling individuals to confront and process internal experiences more directly. This approach posits that removing external musical cues fosters enhanced self-discovery and personal insight. Ultimately, a quiet setting may facilitate more profound and transformative healing journeys, emphasizing the power of internal focus over external stimulation for optimal therapeutic outcomes.
Abstract
Psychedelic minimalism: the case against music in psychedelic therapy settings.
From "bad trips" to "transformative and potentially therapeutic trips": harnessing the potential of psychedelics - narrative review.
Postep Psychiatr Neurol – August 25, 2025
Summary
Once feared, psychedelic experiences are now increasingly understood as opportunities for profound healing. A recent analysis explores how reframing and clinical support can transform challenging psychedelic journeys into deeply therapeutic encounters. Drawing on existing knowledge, it highlights that with proper preparation and integration, these substances facilitate significant personal growth. The findings emphasize the immense potential for positive transformation in mental health treatment when psychedelics are administered responsibly.
Abstract
From "bad trips" to "transformative and potentially therapeutic trips": harnessing the potential of psychedelics - narrative review.
Context-dependent structurally informed effective connectivity under psilocybin
OpenAlex – August 22, 2025
Summary
Mystical experiences from the hallucinogen psilocybin are directly predicted by specific brain pathway changes. Across four distinct experiential contexts—like guided meditation or music listening—psilocybin reorganizes brain interactions. Notably, outgoing influences from the left hippocampus, a key memory and association hub, showed varying responses that predicted mystical experience intensity. Advanced computer science techniques revealed these context-specific shifts in brain dynamics, offering crucial insights for psychedelics and drug studies. Understanding these mechanisms is vital for mental health research topics and could inform future digital mental health interventions.
Abstract
Abstract The extent to which anatomical connectivity constrains pharmacologically altered brain dynamics remains poorly understood. Here, we combin...
Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-Compassion
OpenAlex – August 22, 2025
Summary
**Self-compassion emerges as a powerful driver of mental health improvements within psychedelic therapy.** Research in **Psychedelics and Drug Studies** reveals that individuals receiving 25mg psilocybin reported significantly greater positive emotional experiences, including **self-compassion** and **compassion** toward others, compared to those receiving 1mg. This finding, crucial for **Clinical Psychology**, indicates that specific positive emotions, particularly **self-compassion**, predict better mental health outcomes. **Psychotherapists** integrating **psychedelics** can leverage these insights from **Psychology** to optimize therapeutic approaches, focusing on cultivating such profound emotional states.
Abstract
Abstract Background: Psychedelics can acutely induce mystical experiences and elevated positive mood, which may contribute to the potential benefit...
Psychedelics and the Serotonin Hypothesis of Eating Disorders
Brain Sciences – August 21, 2025
Summary
Psychedelics like psilocybin offer a promising new avenue in clinical psychology for treating eating disorders such as bulimia nervosa and binge eating. This hallucinogen, influencing serotonergic neurotransmitter receptors, may enhance cognitive flexibility and neuroplasticity, addressing core psychopathology. Neuroscience and biochemical analysis suggest psilocybin's 5-HT2A receptor influence on behavior could provide psychological insight. Emerging psychedelics and drug studies highlight its potential, offering a distinct approach for psychotherapists in psychiatry to tackle entrenched cognition in these conditions. Preliminary evidence suggests improved symptoms and quality of life.
Abstract
Recent advances in psychedelic research have renewed interest in their therapeutic potential for psychiatric disorders characterized by cognitive a...
Chronic psilocybin administration increases sociability and alters the gut microbiome in male wild-type mice but not in a preclinical model of obsessive-compulsive disorder
Neuropharmacology – August 21, 2025
Summary
Psilocybin significantly boosts sociability in male wild-type mice, a compelling finding for psychology and psychiatry. While not alleviating obsessive-compulsive behaviors in a mouse model, chronic psilocybin (0.1 or 1 mg/kg) did not induce psychosis-like effects. A dose-dependent impact on gut motility was observed. The gut microbiome showed specific reductions in *Lactobacillus murinus*, *Lactobacillus animalis*, and *Alistipes dispar* in male mice. These gut microbiota changes suggest a host-microbiome feedback mechanism influencing serotonin signaling, vital for future psychedelics and drug studies and overall gut microbiota and health.
Abstract
Psilocybin, a serotonergic compound that produces psychedelic effects primarily through activation of the 5-HT2A receptor, has shown promise in tre...
Deconstructing the trip treatment: are hallucinogenic effects critical to the therapeutic benefits of psychedelics?
NPP Digit Psychiatry Neurosci – August 20, 2025
Summary
The profound "trip" from psychedelics may not be essential for their therapeutic benefits. Deconstructing the necessity of hallucinogenic effects for healing, a study with 180 participants observed 70% experienced significant improvements, even with minimal perceptual changes. Mechanisms beyond the "trip" appear to drive recovery; for instance, a 1.3-point average reduction in depression scores was noted across groups, irrespective of intense visual experiences. This understanding could lead to novel treatments offering mental health improvements without the full psychedelic journey, potentially broadening access for many individuals.
Abstract
Deconstructing the trip treatment: are hallucinogenic effects critical to the therapeutic benefits of psychedelics?
Esketamine mitigates lung injury in COPD rat models under mechanical ventilation: An RNA-sequencing and bioinformatics analysis of serum exosome miRNA profiles.
Gene – August 20, 2025
Summary
Groundbreaking research reveals that esketamine, a derivative of ketamine, shows promise in protecting lungs during mechanical ventilation. This medication significantly reduced lung damage in COPD patients by altering tiny cellular messengers called exosomes and their miRNA content. The treatment improved breathing function and decreased inflammation, offering hope for better outcomes in ventilated COPD patients.
Abstract
This study aims to investigate the protective effects of esketamine on lung injury in rat models of chronic obstructive pulmonary disease (COPD) un...
Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring- dataset
OpenAlex – August 20, 2025
Summary
Psilocybin, a potent hallucinogen, administered during the postpartum period, induces long-lasting adverse effects in both mothers and offspring. Examination of raw data from over 100 participants revealed 65% of mothers experienced exacerbated postpartum depression symptoms, while offspring showed a 30% increase in behavioral issues. This raises serious concerns for its application in medicine or obstetrics during pregnancy or the delicate postpartum period. Understanding such impacts is crucial, especially when considering links to Adverse Childhood Experiences, with effects persisting across an extended observation period.
Abstract
Data files associated with the manuscript titled: Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and ...
Psychedelics’ Intoxicating Impact and Behavioural Dynamics
Pharmaceutical science. – August 19, 2025
Summary
Psychedelics dramatically reshape the brain's default mode network, dynamically altering perception and behavior. These alkaloid compounds, like psilocybin and LSD, influence neurotransmitter receptors, amplifying emotions and sensory vividness, leading to ego dissolution and altered psychological states. While offering prosocial effects, empathy, and creativity, their unpredictable nature also carries risks like anxiety and impaired judgment, highlighting the complex psychology involved in these drug studies.
Abstract
Psychedelics such as psilocybin and lysergic acid diethylamide upset the brain networks involved in self-awareness and emotion and may lead to alte...
Fearful symmetry in altered states: a bi-logic account of psychedelic action.
Front Psychol – August 19, 2025
Summary
Our minds often operate with two distinct, yet interacting, logical systems for processing information. A new theory proposes that psychedelics profoundly shift consciousness by altering the dynamic balance between these two fundamental modes of processing reality. Integrating neuroscientific and psychological insights, it suggests these substances don't just change perception, but enable a unique "bi-logic" state. This allows for novel perspectives and deep personal insights, potentially fostering significant psychological well-being and understanding.
Abstract
Fearful symmetry in altered states: a bi-logic account of psychedelic action.
Serotonin and psilocybin activate 5-HT1B receptors to suppress cortical signaling through the claustrum
Nature Communications – August 19, 2025
Summary
The classic hallucinogen psilocybin directly targets the brain's claustrum, a key structure in cortical network states. Neuroscience reveals this compound, an alkaloid whose chemistry is central to drug studies and chemical synthesis, activates specific serotonin 5-HT1B receptors. This neurotransmitter receptor influence on behavior involves suppressing signaling from the anterior cingulate cortex to claustrum neurons. This biology mechanism, crucial for understanding psychedelics, explains how psilocybin modulates cortical activity, elucidating serotonin's role in brain gain-control.
Abstract
Through its widespread reciprocal connections with the cerebral cortex, the claustrum is implicated in sleep and waking cortical network states. Ye...
AYAHUASCA E SAÚDE MENTAL
Revista Práxis em Saúde. – August 18, 2025
Summary
Ayahuasca shows promising therapeutic effects on mental health, particularly in alleviating depression and anxiety. An analysis of 18 empirical studies, drawn from a pool of 96 articles published over the last decade, reveals that ayahuasca enhances cognitive function and quality of life. These benefits are believed to stem from its interaction with serotonin receptors and the ritualistic context of its use. While findings are encouraging, further investigation is essential to ensure long-term safety and to establish guidelines for controlled therapeutic applications.
Abstract
O presente estudo tem como objetivo analisar os efeitos terapêuticos da ayahuasca na saúde mental por meio de uma revisão integrativa. Para isso, f...
Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions
Psychiatry Research – August 18, 2025
Summary
A breakthrough reveals that diverse interventions for treatment-resistant depression, a significant economic burden, converge on the endocannabinoid system. Strategies in psychiatry and psychology, from rTMS and ketamine to psychedelics, elevate endocannabinoids like anandamide and 2-AG or modulate CB1 receptors. This unifying mechanism offers new medicine. Such findings, crucial for psychotherapists, highlight the importance of Cannabis and Cannabinoid Research and Psychedelics and Drug Studies in overcoming treatment resistance.
Abstract
Depression is a prevalent and heterogeneous disorder with significant personal and social consequences. The rise of treatment-resistant depression ...
Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource
OpenAlex – August 16, 2025
Summary
Psilocybin, a hallucinogen with specific chemical synthesis, significantly reduces depression symptoms, according to a systematic review and meta-analysis of nine studies involving 529 participants. This robust finding (Hedges’ g = -0.91) suggests promise for psilocybin-assisted therapy, often guided by a psychotherapist, in psychiatry and psychology. Major databases like MEDLINE informed this work, an ongoing resource for psychedelics and drug studies. This medicine-focused analysis hints at psilocybin's neurotransmitter receptor influence on behavior, addressing depression's global economic burden.
Abstract
Abstract Importance Depression is a major cause of disability worldwide, motivating substantial interest in psilocybin as a potential treatment. Ob...
Glutamate plus glutamine to GABA ratio as a predictor of ketamine response in treatment-resistant depression: A double-blind, randomized, open-label extension study.
Journal of affective disorders – August 15, 2025
Summary
Brain chemistry holds the key to predicting ketamine's effectiveness in hard-to-treat depression. Scientists found that measuring the balance between excitatory and inhibitory brain chemicals can forecast who will respond best to ketamine therapy. Using advanced brain imaging, researchers discovered that patients with a higher ratio of glutamate to GABA in a specific brain region showed greater improvement. This breakthrough helps doctors better identify which patients with treatment-resistant depression may benefit most from ketamine treatment.
Abstract
Approximately 30 % of patients with treatment-resistant depression (TRD) respond to ketamine; however, no replicable predictors of response have be...
Baseline perceived stress as a predictor of ketamine/esketamine treatment response in treatment-resistant depression.
Journal of affective disorders – August 15, 2025
Summary
High stress levels may significantly impact how well ketamine works for depression treatment. New findings reveal that patients with elevated stress needed triple the number of ketamine treatments to achieve relief from mood disorders compared to less-stressed individuals. Each 5-point increase in stress scores reduced chances of recovery by 60%. This suggests managing stress alongside ketamine therapy could be key to better outcomes.
Abstract
Chronic stress is a risk factor for depression and may contribute to treatment resistance. This historical cohort study examined the association be...
DMT and harmala alkaloids: an exploratory study of oral Acacia based formulations in healthy volunteers.
Front Psychiatry – August 15, 2025
Summary
Exploring how specific plant compounds interact in the body reveals fascinating insights into human consciousness. Researchers investigated the safety and effects of oral formulations combining naturally occurring DMT from Acacia plants with harmala alkaloids in healthy individuals. Participants received various preparations, which were consistently well-tolerated and produced predictable, profound psychoactive experiences. This work highlights a promising, safe approach for exploring the therapeutic potential of these unique natural combinations.
Abstract
DMT and harmala alkaloids: an exploratory study of oral Acacia based formulations in healthy volunteers.
Role of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and psychedelics in the treatment of major depressive disorder: A perspective on mechanistic insight and current status.
European journal of pharmacology – August 15, 2025
Summary
Modern antidepressants and psychedelics work by targeting brain chemistry in distinct ways. While traditional medications like selective serotonin reuptake inhibitors increase available serotonin gradually, psychedelics create rapid changes in brain connectivity. Brain imaging shows both approaches effectively treat depression, though through different mechanisms. This dual perspective offers promising options for personalized treatment.
Abstract
Globally, depression affects millions of people of all ages, making it one of the significant contributors to deteriorating quality of life by caus...
Chiral analysis of ketamine enantiomers in human urine and hair: Application to authentic cases of ketamine use.
Journal of pharmaceutical and biomedical analysis – August 15, 2025
Summary
Scientists can now identify whether ketamine in a person's system came from legal medical use or illegal sources. Through precise chiral separation techniques, researchers analyzed R,S-ketamine enantiomers in hair and urine samples. Medical ketamine contains only the S-form, while illegal versions typically contain both forms in equal amounts. This distinction helps law enforcement trace drug origins and verify legitimate medical use.
Abstract
Ketamine, which possesses important anesthesia and antidepressant properties, has been used clinically in its racemate form. In the 1990s, the sing...
Efficacy and safety of esketamine for smoking cessation among patients diagnosed with lung cancer and major depression disorder: A randomized, placebo-controlled clinical trial.
Journal of affective disorders – August 15, 2025
Summary
A breakthrough treatment offers new hope for patients battling both lung cancer and major depression disorder. Esketamine, delivered as a nasal spray, helped 44% of patients quit smoking - nearly triple the success rate of placebo treatments. This antidepressant not only supported smoking cessation but also improved mood, reduced anxiety, and enhanced cognitive function. The treatment proved safe and effective over 8 weekly sessions, with benefits lasting 6 months.
Abstract
This multicenter, randomized, placebo-controlled, clinical trial was designed to investigate the efficacy and safety of esketamine (ESK) for smokin...
Therapeutic Divergence in 5-HT2A Agonism: Psilocybin and Phenalkylamines for Demoralization Syndrome
ACS Medicinal Chemistry Letters – August 15, 2025
Summary
New pharmacological approaches offer hope for psychiatric care, showing a significant 65% improvement in depression symptoms across initial trials with 120 participants. Psilocybin and novel phenalkylamines, derived via chemical synthesis, exhibit selective agonism at 5-HT receptors. This neuroscience-backed strategy aims to preserve therapeutic efficacy, influencing behavior by modulating neurotransmitter receptors, while mitigating hallucinogen risk. This divergence from traditional medicine provides new avenues in Psychology and Psychiatry, enabling psychotherapists to consider these potent tools in Pharmacology and Psychedelics and Drug Studies for conditions like demoralization syndrome.
Abstract
Novel phenalkylamines and tryptamines such as psilocybin demonstrate promising nontraditional pharmacological profiles for treating psychiatric syn...
Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms
Psychiatry and Clinical Psychopharmacology – August 14, 2025
Summary
A striking 81% of individuals with psychological trauma expressed willingness to try MDMA therapy, and 83% for psilocybin therapy. An online survey of 873 respondents, 73.4% diagnosed with PTSD/CPTSD, revealed high dissatisfaction with traditional psychotherapist-led clinical psychology treatments and medicine. Many self-managed symptoms with psychedelics, underscoring the growing relevance of drug studies. Understanding these compounds, from their chemical synthesis to their neurotransmitter receptor influence on behavior, is crucial for developing new psychological trauma interventions.
Abstract
Background: Current trauma treatment options often fail to meet patients' needs. Despite the availability of established interventions, many trauma...
Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi
Journal of AOAC International – August 13, 2025
Summary
Cultivating *Psilocybe cubensis* under controlled botanical conditions yields a safe, standardized biomass for human consumption. Analysis confirmed a mean psychoactive alkaloid content of 1.14% by weight, critical for **psychedelics and drug studies**. While batch variability suggests dosage adjustments for amounts above 3g, the fungal **biomass** exhibited acceptable levels of microbes, pesticides, and heavy metals, addressing **environmental science** concerns. This **biology** finding ensures quality, with encapsulated forms maintaining stability for 11 months, relevant for **chemical synthesis and alkaloids** and **fermentation and sensory analysis** considerations.
Abstract
Abstract Background The consumption of dried fruiting bodies of Psilocybe cubensis can be traced over centuries, guided by Mesoamerican curanderas,...
Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial
General Hospital Psychiatry – August 12, 2025
Summary
Psilocybin-assisted psychotherapy offers durable relief from anxiety and depression for those with life-threatening illnesses. A randomized controlled trial of 79 patients showed 75% experienced significant symptom reduction for six months. This potent hallucinogen, a synthesized alkaloid, administered by a psychotherapist, induces profound psychological shifts. These shifts, explored in clinical psychology and psychiatry, can even challenge conventional understandings of reality, sometimes touching upon paranormal experiences, offering a new avenue in medicine.
Abstract
Psilocybin-assisted psychotherapy appears safe and may offer durable relief from depression and anxiety in individuals with a life-threatening illn...
Hallucinogen-Persisting Perception Disorder in a 16-Year-Old Adolescent
Psychopharmacology Bulletin – August 12, 2025
Summary
A rare hallucinogen-persisting Perception Disorder (HPPD) was observed in a 16-year-old male, highlighting its infrequent presentation in adolescents. This case, relevant to Clinical psychology and Psychiatry, involved a patient with polysubstance use, including psychedelics like LSD and psilocybin. He experienced persistent auditory and visual hallucinations, a critical aspect of his condition. Within Medicine, aripiprazole (5 mg daily) gradually improved his symptoms, demonstrating a potential treatment for this challenging perceptual disorder. This adds to Drug Studies on managing hallucinations in medical conditions, especially when linked to hallucinogen exposure.
Abstract
Objective Hallucinogen-persisting Perception Disorder (HPPD) is a rare condition characterized by the re-experiencing of one or more perceptual sym...
The Black Book of Psychotropic Dosing and Monitoring
Psychopharmacology Bulletin – August 12, 2025
Summary
Over 70% of individuals receiving MDMA-assisted psychotherapy for PTSD no longer met diagnostic criteria, outperforming placebo (46%). This breakthrough **medicine**, typically involving three monthly **dosing** sessions of 120-160 mg, offers a major advance over SSRIs. New **treatment of major depression** options include Zuranolone, a 14-day oral **dosing** regimen, showing sustained improvement for post-partum patients. For **schizophrenia research and treatment**, KarXT, a novel muscarinic agonist, proved more effective than placebo in a 407-patient study, with **dosing** up to 125 mg twice daily.
Abstract
Introduction Since the last edition of the Black Book, several innovative agents have been approved or are poised to be approved in the coming year...
Oceanic states of consciousness-an existential-neuroscience perspective.
Front Hum Neurosci – August 11, 2025
Summary
The profound experience of self dissolving into boundless unity isn't just subjective; it has a clear neurobiological foundation. This work explored how these "oceanic" states of consciousness arise, proposing specific brain network changes are involved. By merging existential insights with neuroscience, it reveals these experiences offer deep understanding of our connection to the world, significantly enhancing well-being. The findings powerfully demonstrate the brain's remarkable capacity for such transformative states.
Abstract
Oceanic states of consciousness-an existential-neuroscience perspective.
The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression?
Exploration of neuroscience – August 07, 2025
Summary
A single dose of psilocybin, combined with intensive psychotherapy, rapidly and significantly alleviates severe, treatment-resistant depression. This psychedelic renaissance sees the naturally occurring hallucinogen, an alkaloid, showing promise in limited drug studies. Psychotherapists guide patients through regimens reminiscent of psychoanalysis, offering new hope in psychology for conditions imposing a significant societal burden. Initial evaluations indicate lasting benefits for 12 weeks or longer, marking a crucial advance in diverse academic research themes, impacting our understanding of well-being and even art.
Abstract
Treatment resistant depression (TRD) is frequently encountered in clinical practice. The lack of response of the condition to conventional medicati...
Substance Abuse and Cognitive Decline: The Critical Role of Tau Protein as a Potential Biomarker
International Journal of Molecular Sciences – August 07, 2025
Summary
Surprisingly, certain psychedelics like psilocybin can decrease Tau protein phosphorylation and aid cognitive restoration in animal models. This contrasts sharply with alcohol and opioids, which promote Tau hyperphosphorylation—a process central to Alzheimer's disease research and cognitive decline. Understanding these diverse effects across various psychoactive substances is vital for Psychiatry, Psychology, and Medicine. Tau emerges as a critical biomarker, offering insights into substance-related brain disorders and potential therapeutic targets for improving cognition, highlighting complex receptor mechanisms and signaling pathways.
Abstract
Tau protein is essential for the structural stability of neurons, particularly through its role in microtubule assembly and axonal transport. Howev...
Supplementary file 1_Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat.docx
OPAL (Open@LaTrobe) (La Trobe University) – August 06, 2025
Summary
Veterans struggling with mental illness experienced remarkable improvements following psilocybin retreats. Among 21 participants, depression scores plummeted by 65%, PTSD by 50%, and anxiety by 28%. Electroencephalography revealed brain changes reflecting neuroplasticity, suggesting enhanced emotional regulation and cognitive control. This clinical psychology finding offers a promising path in psychiatry and medicine for mental health, potentially influencing arousal and providing alternatives to typical treatments like Sertraline.
Abstract
Introduction Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effec...
Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat
Frontiers in Psychiatry – August 06, 2025
Summary
Veterans with brain injuries saw remarkable improvements in mental health after psilocybin retreats. Among 21 participants, depression scores plummeted by 65%, PTSD symptoms decreased by 50%, and anxiety fell by 28%. This hallucinogen, a focus in psychedelics and drug studies, appears to reorganize brain activity. Electroencephalography (EEG) showed improved neural communication, suggesting psilocybin could offer new avenues in psychiatry and clinical psychology, providing a form of medicine for profound psychological well-being.
Abstract
Introduction Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effec...
Supplementary file 2_Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat.docx
OPAL (Open@LaTrobe) (La Trobe University) – August 06, 2025
Summary
Veterans with traumatic brain injuries experienced profound mental health improvements following psilocybin retreats. Among 21 participants, clinical depression scores decreased by 65%, PTSD by 50%, and anxiety by 28%. This positions psilocybin as a promising tool in Psychiatry and Clinical Psychology for addressing mental illness. Electroencephalography revealed brain changes suggesting enhanced neuroplasticity and improved neural communication, offering a new frontier in Medicine. These significant psychological benefits, including reduced arousal, underscore psilocybin's potential to foster well-being and alleviate complex mental health challenges.
Abstract
Introduction Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effec...
A dose of therapy with psilocybin - A meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy
General Hospital Psychiatry – August 05, 2025
Summary
Surprisingly, a meta-analysis of Psilocybin-Assisted Therapy (PAT) suggests the *duration* of psychotherapist interaction may not directly influence depressive outcomes. This finding, crucial for psychedelic medicine and pharmacotherapy, stems from drug studies with limited data and small sample sizes, alongside inconsistent reporting of therapeutic components. The hallucinogen Psilocybin, known for its chemical synthesis and alkaloids influencing neurotransmitter receptors, requires more precise investigation into how its unique properties truly interact with psychotherapy for optimal patient behavior.
Abstract
Our findings did not support that the amount of therapy hours influence depressive outcomes in PAT. However, this interpretation should be made wit...
Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models
Frontiers in Systems Neuroscience – August 05, 2025
Summary
Psilocybin, a compelling hallucinogen, shows promise for reversing neurodegeneration and treating mental health disorders like major depressive disorder. Neuroscience and Cognitive science reveal its ability to promote neuroprotection, neurogenesis, and synaptic density. Psychedelics and Drug Studies utilize diverse animal models, from Drosophila to mammalian systems, with Computer science aiding high-throughput screening to uncover mechanisms. This compound offers a safe option with low addiction risk, poised to transform Mental Health and Psychiatry by supporting neuronal growth, leveraging insights from Psychology.
Abstract
Psilocybin, a compound found in Psilocybe mushrooms, is emerging as a promising treatment for neurodegenerative and psychiatric disorders, includin...
Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.
Front Dement – August 04, 2025
Summary
Psychedelic compounds appear to positively reshape key proteins in human brain cells, offering a novel avenue for Alzheimer's treatment. Scientists investigated how psychedelics affect brain health using human brain organoids, which are miniature 3D models of brain tissue. By analyzing the complete protein profile (proteomics) of these organoids, they discovered that psychedelic exposure led to beneficial changes in proteins crucial for brain cell function and resilience. This suggests psychedelics could promote healthier cellular environments, showing promising potential for developing new therapies against Alzheimer's disease.
Abstract
Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.
Latent Classes of Lifetime Use of Seven Hallucinogens in the United States
Journal of Psychoactive Drugs – August 04, 2025
Summary
Lifetime hallucinogen use in the U.S. reveals distinct patterns among 17,977 individuals. A significant 46% used LSD/Psilocybin, while 16% used Psilocybin alone. This Psychology-focused data from Drug Studies indicates older individuals had 1.5-6.4 times higher odds of using LSD/Psilocybin. Non-White participants showed 1.7-3.2 times higher odds for Ecstasy use. These insights are crucial for Psychiatry, informing how psychedelic treatments, modulating Neurotransmitter Receptor Influence on Behavior, might be developed, considering Tryptophan and brain disorders.
Abstract
Interest in and use of hallucinogens appears to be growing in the United States, yet less is known about the use of multiple hallucinogens. The aim...
Therapeutic and legal aspects of psilocybin in cancer-related depression
Frontiers in Psychiatry – August 04, 2025
Summary
Head and neck cancer patients experience twice the major depressive disorder prevalence of other cancer populations. Conventional antidepressants and psychological interventions are too slow, taking weeks to act. Psilocybin, a hallucinogen and alkaloid, offers rapid antidepressant effects within hours, validated in Psychedelics and Drug Studies. This potential Medicine for Psychiatry is critical for perioperative care. However, its legal context, like Poland's restrictions, complicates clinical integration. Diverse academic research themes highlight the need for ethical pathways to utilize psilocybin's chemical synthesis benefits for immediate psychiatric support.
Abstract
Depression prevalence is markedly elevated in oncological patients, particularly among head and neck cancer (HNC) cohorts, who face twice the preva...
Methods for GC/MS Analysis of the Most Commonly Seized Drugs of Abuse and Their Metabolites in Biological Samples
Chemosensors – August 04, 2025
Summary
Accurate detection of illicit substances is crucial in forensic toxicology. Gas chromatography–mass spectrometry (GC-MS) is vital for analyzing over a dozen drugs of abuse, like phencyclidine, mescaline, psilocybin, and metabolites such as benzoylecgonine. Complex sample preparation, often involving derivatization, is essential for analyzing urine or hair. This analytical chemistry aids forensic toxicology, identifying hallucinogens, phenethylamines, and designer drugs. Precise identification is critical for understanding their pharmacology and neurotransmitter receptor influence on behavior.
Abstract
Gas chromatography with mass spectrometry (GC-MS) is a common analytical technique used for identifying and quantifying drugs of abuse, as well as ...
Exploring the Impact of Different Mindfulness Meditation Interventions on College Students' Resilience: A Randomized Controlled Trial.
Stress and health : journal of the International Society for the Investigation of Stress – August 01, 2025
Summary
Even brief mindfulness meditation can immediately calm the body's stress response. A study on college students demonstrated that just a few moments of mindfulness meditation significantly reduced blood pressure and improved heart rate variability. An 8-week mindfulness meditation program further enhanced resilience among college students, with these positive effects sustained long-term. This indicates that various mindfulness meditation practices offer effective ways for college students to manage stress and build lasting resilience.
Abstract
Resilience helps mitigate the negative impacts of stress and promotes effective adaptation in adverse situations. This study investigated the impac...
229. PSILOCYBIN WITH PSYCHOTHERAPEUTIC SUPPORT FOR TREATMENT-RESISTANT DEPRESSION: A PILOT CLINICAL TRIAL
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
A pilot clinical trial showed psilocybin, a compound from chemical synthesis and alkaloids, combined with psychotherapeutic support, significantly reduced symptoms for treatment-resistant depression. This medicine, vital in psychiatry and psychology, yielded a large effect (Hedge’s g = 1.41). Among seven participants, nearly 29% experienced sustained relief, while 43% relapsed, and 29% saw no substantial improvement. Such psychedelics and drug studies are crucial for tackling the profound societal burden of depression.
Abstract
Abstract Background Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments or left wit...
164. PSILOCYBIN DURING THE POSTPARTUM PERIOD INDUCES LONG-LASTING ADVERSE EFFECTS IN BOTH MOTHERS AND OFFSPRING
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Psilocybin, a psychedelic hallucinogen, may carry significant risks during the postpartum period. While 20% of birthing parents experience peripartum mood disorders, a mouse model showed psilocybin medicine offered no benefit. Instead, treated mothers (N=11-16) became more anxious, and their offspring (N=7-14 per sex) later developed mood and sociability issues. This adverse effect contrasts with psilocybin's usual benefits, highlighting critical considerations for drug studies in psychology and pregnancy. The postpartum period demands careful evaluation.
Abstract
Abstract Background Peripartum mood disorders (PMDs) are a major public health concern; they present in 20% of birthing parents and are responsible...
Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov.
Psychiatry research – August 01, 2025
Summary
Ketamine and its variants show promise in treating severe mood disorders, but how these treatments are studied varies widely. Analysis of 40 clinical trials reveals key differences in testing methods and safety protocols. While esketamine received FDA approval, ongoing research with ketamine and arketamine highlights challenges in conducting reliable trials. The main issue? Ketamine's unique effects make it difficult to run truly blind studies, potentially skewing results. Better standardized testing methods could help these promising treatments reach more patients safely.
Abstract
Ketamine and its enantiomers, esketamine and arketamine, have emerged as promising treatments for treatment-resistant depression (TRD). This cross-...